Clinical Trial News and Research

RSS

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

More evidence supporting cardiac danger of painkillers after MI

Heart attack survivors who use nonsteroidal anti-inflammatory drugs have an increased risk for long-term mortality or a second heart attack, research suggests.

12 Sep 2012

Readily available index provides practical landmarks for glaucoma patients

The mean deviation index, a widely understood metric for summarizing damage to an individuals’ visual field, could help physicians estimate practical landmarks in patients with glaucoma such as fitness to drive, report UK researchers.

12 Sep 2012

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Oncolytics Biotech Inc. today provided an update on its Phase III trial of REOLYSIN in combination with carboplatin and paclitaxel for the treatment of head and neck cancers (REO 018).

12 Sep 2012

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

Transcept Pharmaceuticals, Inc. today announced that it has completed enrollment in its Phase 2 clinical trial evaluating TO-2061 added as adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to first-line treatment with an approved OCD medication.

12 Sep 2012

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).

12 Sep 2012

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

UCLA stem cell researchers have found that a gene therapy regimen can safely restore immune systems to children with so-called "Bubble Boy" disease, a life threatening condition that if left untreated can be fatal within one to two years.

12 Sep 2012

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

"The leading candidate to become the world's first vaccine against dengue fever was only 30 percent effective in its first large clinical trial, dealing at least a temporary setback to efforts to control a disease that threatens half the world's population," the New York Times reports.

12 Sep 2012

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

e-Therapeutics plc announces that it has started a second phase I clinical trial of its anti-cancer drug ETS2101. This trial will enrol up to 45 patients with a variety of solid tumours at two UK centres, St James's University Hospital in Leeds and the Northern Centre for Cancer Care at the Freeman Hospital in Newcastle.

12 Sep 2012

KaloBios commences KB003 Phase 2 trial in severe asthma

KaloBios Pharmaceuticals, Inc. today announced that dosing has begun in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of KB003, the company's anti-GM-CSF Humaneered monoclonal antibody, in subjects with severe asthma uncontrolled by corticosteroids.

12 Sep 2012

Palatin fourth quarter revenues decrease to $11,000

Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2012.

11 Sep 2012

DATATRAK announces technology and services agreement with Bellicum

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the award of a multi-million dollar, five-year technology and services agreement with Bellicum Pharmaceuticals.

11 Sep 2012

CHLA, House Research Institute and University of Verona to advance ABI use in children

House Research Institute and Children's Hospital Los Angeles have announced an international consortium with the University of Verona in Italy to collaborate on teaching and research to advance the use of the Auditory Brainstem Implant (ABI) in children worldwide.

11 Sep 2012

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Pergamum AB announced today that dosing has begun in a randomized Phase I/II trial of LL-37 for the treatment of patients with hard-to-heal venous leg ulcers.

11 Sep 2012

Cardiac stem cells from newborns show stronger regenerative ability

Researchers at the University of Maryland School of Medicine, who are exploring novel ways to treat serious heart problems in children, have conducted the first direct comparison of the regenerative abilities of neonatal and adult-derived human cardiac stem cells.

11 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Palatin Technologies, Inc. today announced that the last patient has completed treatment in its Phase 2B clinical trial evaluating the efficacy and safety of bremelanotide for treatment of female sexual dysfunction (FSD).

11 Sep 2012

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Florida Hospital Tampa and Dr. James E. Lefler are the first in the Tampa Bay area to adopt the new FDA approved device called the Trevo Pro Clot Retriever manufactured by Stryker. The Trevo Pro is the next generation in clot removal technology.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Less than half of community-based substance abuse treatment programs in the United States currently make HIV testing available on-site or through referral. A new study led by researchers at Weill Cornell Medical College shows the cost-effectiveness of integrating on-site rapid HIV testing into drug treatment programs.

10 Sep 2012

Clinical Trial News and Research

Sanofi Aventis receives FDA approval for Aubagio to treat relapsing forms of MS

More evidence supporting cardiac danger of painkillers after MI

Readily available index provides practical landmarks for glaucoma patients

Data from Oncolytics’ REOLYSIN Phase III combination trial on head and neck cancers

Transcept completes enrollment in TO-2061 Phase 2 trial for obsessive compulsive disorder

MD Anderson joins API’s Actimab-A Phase I/II trial in acute myeloid leukemia

Gene therapy regimen can safely restore immune systems to children with Bubble Boy disease

Leading dengue fever vaccine candidate 30% effective in first large clinical trial

e-Therapeutics initiates second ETS2101 phase I trial in solid tumours

KaloBios commences KB003 Phase 2 trial in severe asthma

Palatin fourth quarter revenues decrease to $11,000

DATATRAK announces technology and services agreement with Bellicum

CHLA, House Research Institute and University of Verona to advance ABI use in children

Pergamum initiates LL-37 Phase I/II trial in hard-to-heal venous leg ulcers

Cardiac stem cells from newborns show stronger regenerative ability

Flow cytometry renders PCR testing unnecessary for most AML patients

Palatin Technologies completes bremelanotide Phase 2B trial on female sexual dysfunction

Florida Hospital Tampa adopts FDA approved Trevo Pro Clot Retriever

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Study measures cost-effectiveness of on-site rapid HIV testing in drug abuse treatment programs

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer